Anzeige
Mehr »
Login
Sonntag, 26.01.2025 Börsentäglich über 12.000 News von 683 internationalen Medien
US-Präsident setzt auf die Solana Blockchain! Diese Krypto-Perle profitiert enorm!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
375 Leser
Artikel bewerten:
(0)

Olympus' ENDOEYE FLEX 3D Articulating Videoscope Receives Breakthrough Innovation Technology Award at Premier, Inc.'s 2014 National Breakthroughs Conference

Finanznachrichten News

CENTER VALLEY, Pa., June 11, 2014 /PRNewswire/ --Olympus, a global technology leader in delivering innovative diagnostic and therapeutic solutions for medical and surgical procedures, among other core businesses, announced today that its ENDOEYE FLEX 3D articulating videoscope was one of 16 medical innovations on display in front of thousands of healthcare providers and experts at the at the Premier, Inc. 2014 Breakthroughs Conference and Exhibition.

Olympus' ENDOEYE FLEX 3D articulating videoscope received the Breakthrough Innovation Technology Award at the Premier, Inc. 2014 Breakthroughs Conference and Exhibition. The Olympus ENDOEYE FLEX 3D is the world's only articulating HD 3D video laparoscope that helps restore the surgeon's natural 3D vision and depth perception during surgical procedures.

Olympus' 3D Imaging System was showcased during the conference's sixth annual Innovation Celebration, which recognizes advances in healthcare while highlighting industry suppliers committed to innovation and improving patient outcomes.

"We are honored to be recognized by Premier for innovative technology that will help physicians and surgeons improve the overall care of their patients," said Luke Calcraft, President of the Medical Systems Group at Olympus Corporation of the Americas. "Olympus is fully committed to helping healthcare facilities fulfill the requirements of healthcare reform aimed at improving quality of care, decreasing costs and enhancing patient satisfaction."

Olympus' ENDOEYE FLEX 3D is the world's only articulating HD 3D videoscope. The system's 3D visualization provides depth perception and a precise spatial view of anatomy that cannot be achieved with traditional 2D systems, producing bright, natural 2D and 3D images in a lightweight and ergonomic design. It also delivers up to 100 degrees of articulation in all directions, enabling observation and therapy in the entire peritoneal cavity - and with a level visual horizon.

When compared with traditional 2D surgical systems, the ENDOEYE FLEX 3D delivers value to surgeons and patients by reducing surgical errors and improving the speed, accuracy and precision of surgical tasks such as dissection, grasping and suturing, based on internal Olympus testing conducted using a simulated surgical model.* Olympus' 3D system also provides surgeons with real time tactile feedback, which is lost when using robotic alternatives.

The modular design of the Olympus 3D Imaging System makes it easy to add 3D capability to existing Olympus EVIS EXERA III universal imaging systems, reducing the investment necessary to add 3D capability. The EVIS EXERA III system is compatible with more than 100 endoscopes and camera heads. This compatibility is retained even after upgrading to 3D, helping to reduce capital investments and simplify asset management and training. Olympus 3D Imaging also is seamlessly integrated into the Olympus ENDOALPHA Integrated Operating Room.

"Those who attend and participate in the Innovation Celebration share Premier's commitment to providing valuable products to our members that are safe, high-quality and cost-effective," said Durral R. Gilbert, president of supply chain services, Premier. "We believe these innovations can benefit providers as they work to transform healthcare."

Award winners were announcedJune 10, 2014,during the Innovation Celebration held at the Henry B. Gonzalez Convention Centerin San Antonio, Texas.

For more information or to evaluate the Olympus ENDOEYE FLEX 3D system, please contact your Olympus representative or call 800-548-5515.

About Premier, Inc.
Premier, Inc. is a leading healthcare improvement company, uniting an alliance of approximately 3,000 U.S. hospitals and 110,000 other providers to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions, and advisory and other services, Premier enables better care and outcomes at a lower cost. Premier, a Malcolm Baldrige National Quality Award recipient, plays a critical role in the rapidly evolving healthcare industry, collaborating with members to co-develop long-term innovations that reinvent and improve the way care is delivered to patients nationwide. Headquartered in Charlotte, N.C., Premier is passionate about transforming American healthcare. Please visit Premier's news and investor sites on www.premierinc.com; as well as Twitter, Facebook, LinkedIn, YouTube, Instagram, Foursquare and Premier's blog for more information about the company.

About Olympus Medical Systems Group
Olympus Medical Systems Group, a division of global technology leader Olympus, develops solutions for healthcare professionals that help improve clinical outcomes, reduce overall costs and enhance quality of life for their patients. By enabling less invasive procedures, innovative diagnostic and therapeutic endoscopy, and early stage lung cancer evaluation and treatments, Olympus is transforming the future of healthcare.

For more information visit Olympus at medical.olympusamerica.com.

*Data on file.

Photo - http://photos.prnewswire.com/prnh/20140610/116520

SOURCE Olympus

© 2014 PR Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.